MISBA
LIVE

Serial Number

79440214

Owner

Harness Therapeutics Limited

Attorney

Rebecca Liebowitz

Filing Date

Nov 26, 2025

Add to watchlist:

No watchlists yet
View on USPTO

MISBA Trademark

Serial Number: 79440214

MISBA is a trademark filed by Harness Therapeutics Limited on November 26, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Harness Therapeutics Limited (4 trademarks)

Minerva Building (B250),

Entity Type: 98

Trademark Details

Filing Date

November 26, 2025

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for the treatment and prevention of ophthalmological conditions, hearing loss, hematologic diseases, immune response disorders, autoimmune conditions and disorders, neurological disorders, neurodegenerative disorders, psychiatric disorders, respiratory diseases, fibrosis, hepatic diseases, renal diseases, diseases of the pancreas, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; medical and veterinary preparations for therapeutic purposes, for the treatment and prevention of ophthalmological conditions, hearing loss, hematologic diseases, immune response disorders, autoimmune conditions and disorders, neurological disorders, neurodegenerative disorders, psychiatric disorders, respiratory diseases, fibrosis, hepatic diseases, renal diseases, diseases of the pancreas, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; biological, chemical and biochemical reagents for medical use; DNA, RNA, oligonucleotides, and polynucleotides for medical and veterinary use; gene editing enzymes for medical and veterinary use; medical and veterinary preparations containing therapeutic DNA and RNA, for the treatment and prevention of ophthalmological conditions, hearing loss, hematologic diseases, immune response disorders, autoimmune conditions and disorders, neurological disorders, neurodegenerative disorders, psychiatric disorders, respiratory diseases, fibrosis, hepatic diseases, renal diseases, diseases of the pancreas, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; biological, chemical and biochemical reagents for medical or veterinary use

Chemicals for scientific purposes; chemicals for use in research; chemicals, enzymes, and biological preparations in the nature of DNA and RNA for research use; chemicals for use in the preparation and creation of DNA and RNA; enzymes for use in the preparation and creation of DNA and RNA; molecular biology research tools in the nature of biological, chemical and biochemical reagents for research use

Scientific and technological services and research and design relating thereto, namely scientific research services in the field of genomics; medical and veterinary research services, including the manipulation of biological reagents to be used for medical, veterinary or therapeutic purposes; chemical and biological analysis and research services; medical and scientific research into DNA and RNA; medical and scientific research and product development into regarding the creation of DNA and RNA; medical and scientific research and product development services in the field of the manufacture of synthetic DNA, RNA, genes and oligonucleotides for others; medical and scientific research, product development, product testing and research laboratory analysis services in the field of genomics, DNA and RNA sequencing, gene synthesis, gene identification, gene cloning, gene expression, and gene mapping; scientific and medical research in the fields of molecular biology, next generation sequencing, high-throughput sequencing, and bioinformatics; medical and scientific research in the fields of DNA and RNA modelling services; gene engineering services; medical and scientific research and product development services regarding the creation of genome libraries or collections of biologicals including chemicals and compounds; medical and scientific research and product development services in regarding creating libraries or collections of normal and mutated genes; scientific services relating to the discovery and the preclinical and clinical development of therapeutic products; medical and scientific research consultancy

Filing History

TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 12, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 12, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 12, 2026 TROA
REFUSAL PROCESSED BY IB
Jun 4, 2026 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 15, 2026 RFCS
REFUSAL PROCESSED BY MPU
May 14, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 31, 2026 RFCR
NON-FINAL ACTION WRITTEN
Mar 30, 2026 CNRT
ASSIGNED TO EXAMINER
Mar 30, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 4, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 4, 2026 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 25, 2025 REPR